LTR Pharma (ASX:LTP) Non Operating Income : A$ Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. LTR Pharma's Non Operating Income for the six months ended in Jun. 2023 was A$-0.02 Mil.

LTR Pharma Non Operating Income Historical Data

The historical data trend for LTR Pharma's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Non Operating Income Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Non Operating Income

-0.02

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Non Operating Income	-	-	-0.02

LTR Pharma Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

LTR Pharma Non Operating Income Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Non Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines